Stephen Morlock Net Worth

The estimated Net Worth of Stephen Morlock is at least $657 millier dollars as of 24 November 2017. Stephen Morlock owns over 330,000 units of BioPharmX stock worth over $454,457 and over the last 10 years Stephen sold BPMX stock worth over $202,505.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Stephen Morlock BPMX stock SEC Form 4 insiders trading

Stephen has made over 7 trades of the BioPharmX stock since 2015, according to the Form 4 filled with the SEC. Most recently Stephen sold 1,125,027 units of BPMX stock worth $202,505 on 18 October 2018.

The largest trade Stephen's ever made was selling 1,125,027 units of BioPharmX stock on 18 October 2018 worth over $202,505. On average, Stephen trades about 82,557 units every 61 days since 2015. As of 24 November 2017 Stephen still owns at least 873,956 units of BioPharmX stock.

You can see the complete history of Stephen Morlock stock trades at the bottom of the page.

What's Stephen Morlock's mailing address?

Stephen's mailing address filed with the SEC is 1098 HAMILTON COURT, , MENLO PARK, CA, 94025.

Insiders trading at BioPharmX

Over the last 10 years, insiders at BioPharmX have traded over $1,425,057 worth of BioPharmX stock and bought 7,392,667 units worth $2,162,100 . The most active insiders traders include Resources Inc Franklin, Capital Viii, Llc Vivo et Stephen Morlock. On average, BioPharmX executives and independent directors trade stock every 79 days with the average trade being worth of $308,564. The most recent stock trade was executed by Pharmaceuticals Llc Timber on 10 February 2020, trading 55,008 units of BPMX stock currently worth $550.

What does BioPharmX do?

BioPharmX Corp. is a specialty pharmaceutical company focused on developing prescription products utilizing its proprietary HyantX Topical Delivery System for dermatology indications. The HyantX delivery system is designed to stabilize and solubilize hydrophilic molecules in an anhydrous gel environment. The company was founded by James R. Pekarsky and Anja B. Krammer on August 30, 2010 and is headquartered in Campbell, CA.

Complete history of Stephen Morlock stock trades at BioPharmX

BioPharmX executives and stock owners

BioPharmX executives and other stock owners filed with the SEC include:

• Lubor Gaal,
  Independent Director
• David Cohen,
  Independent Director
• Edward Sitar,
  Director
• Gianluca Pirozzi,
  Director
• Amir Tavakkol,
  Chief Scientific Officer
• Joyce Goto,
  Chief Accounting Officer
• Zachary Rome,
  Chief Operating Officer, Executive Vice President, Secretary, Director
• Joseph Lucchese,
  Chief Financial Officer, Executive Vice President
• John Koconis,
  Chief Executive Officer, Director
• Michael Derby,
  Executive Chairman of the Board
• Sciences Llc Tardi Med,
  10% owner
• Pharmaceuticals Llc Timber,
  10% owner
• David S Tierney,
  CEO
• Ronald Todd Plott,
  Director
• Stephen Morlock,
  Director
• Kin Foong Chan,
  EVP of R&D
• Anja B Krammer,
  President
• Michael Hubbard,
  Director
• Resources Inc Franklin,
  10% owner
• Capital Viii, Llc Vivo,
  10% owner
• Craig A. Barbarosh,
  Director
• Gregory David Kitchener,
  CFO
• Capital Fund Viii, L.P. Vivo,
  10% owner
• Charles Gregory Vontz,
  Director
• Steven Bosacki,
  Chief Operating Officer